Trade Ideas

 This new activity stream is under development. Feel free to post. It will help us test things out!
Use # when posting tickers. $ will be supported soon.

anyone here?
Please sign up or sign in to like or comment on this post.
sad to see it's dead
Please sign up or sign in to like or comment on this post.
hello new here
Please sign up or sign in to like or comment on this post.
Ben Rabizadeh account is now verified on the site.
Please sign up or sign in to like or comment on this post.
Please sign up or sign in to like or comment on this post.

DRAPER, Utah , Feb. 25, 2016 /PRNewswire/ -- Flexpoint Sensor Systems, Inc. (FLXT) is pleased to announce that 2016 is exceeding expectations and will accelerate (See more) the company's growth.

According to Paul Sexauer, Flexpoint Vice President of Sales and Marketing, "We are experiencing continued successful progress with an American-based, Fortune 500, global toy manufacturing company as it rapidly approaches full-scale production on products utilizing the Bend Sensor®. Pre-production tests have been successful, milestones continue to be met, and mass production timelines are on-track for 2016." As previously announced, production of these toys is being done in coordination with a multi-national supply chain solutions company that offers design, manufacturing, distribution and aftermarket services to original equipment manufacturers. Sexauer further commented, "With each milestone, additional purchase orders with progressively increasing dollar volumes are being received. Flexpoint remains on target to significantly increase revenue during 2016."

In the rapidly growing and emerging Wearables space, Flexpoint has also recently received additional purchase orders from multiple glove manufacturers across various market sub-segments including medical, toys, gaming and virtual reality. The "speed to market" commercialization plans of these companies are driving this increased order volume. Flexpoint is aggressively going after this evolving market, and expects this pattern to continue and dramatically increase in 2016. In aggregate, Bend Sensor® 2016 wearables order volumes are expected to number in the tens of thousands for the year. "The wearables market segment is clearly one where our technology is easily adapted and truly illustrates our technological differentiation. Flexpoint's willingness and ability to customize sensors for these innovative companies and deliver them at a competitive price point allows us to deliver real value to our customers," remarked Sexauer.

Please visit for more information.

About Flexpoint Sensor Systems, Inc.(FLXT)

Flexpoint Sensor Systems, Inc. (FLXT) is an innovative technology firm specializing in developing products that feature the Company's patented Bend Sensor® and related technology. The Bend Sensor® is a groundbreaking sensing solution that is revolutionizing applications in the automotive, safety, medical and industrial industries. The Bend Sensor® single-layer, thin film construction cuts costs and mechanical bulk while introducing a range of functions and stylistic design possibilities that have never before been available in sensing technology. Flexpoint's technology and expertise have been recognized by the world's elite business and academic innovators for over 17 years. The company is setting a new standard for sensing solutions in the "smart" age of technology.

Forward-Looking Statements

This press release contains certain forward-looking statements. Investors are cautioned that certain statements in this release are "forward-looking statements" and involve both known and unknown risks, uncertainties and other factors. Such uncertainties include, among others, certain risks associated with the operation of the company described above. The Company's actual results could differ materially from expected results.

Contact Information:

Flexpoint Sensor Systems (FLXT)
Clark Mower , President

Brokers and Analysts
Chesapeake Group

Please sign up or sign in to like or comment on this post.
Watchlist today BSI DGLY
Please sign up or sign in to like or comment on this post.
VRNG lots of insider buying around the 2.50 level. Not sure what is up.
Please sign up or sign in to like or comment on this post.
Kudos! Excellent coverage on this blatant crime. And it's recurring. Would like to bring up the suggestion of State sponsored attacks as (See more) in China, trying to bring down a defense against invasive products. Double down with issues with the ineptitude or malfeasance of the FINanacial Industry Regulatory Agency.
Please sign up or sign in to like or comment on this post.
#APDN Excerpt of Newsletter from Patrick Cox:
(this was posted in a comment on SeekingAlpha and subsequently deleted by SA)

Noah Katz
I subscribe (See more) to Patrick Cox biotech investment newsletter; here's an excerpt of an email I received today:

" November 2, 2015
Bear Attack on Applied DNA Sciences (and Patrick) Creates Long-Term Buying Opportunity

Dear TransTech Reader,

Last Thursday was a rough one for shares of Applied DNA Sciences.

No, the company did not release any negative news related to any of its products, nor did it issue a share dilution, or anything else that would have a material effect on APDN’s value.

Instead, an anonymous article was published on the website Seeking Alpha that attempted to smear the reputation of APDN, its management, and our editor, Patrick Cox. If you’d like to read it for yourself, it can be found here.

As a team, we hate having to respond to these types of baseless reports, published via a questionable financial website by an anonymous user hiding behind his computer with little to no repercussions. However, this user has caused severe short-term damage to the company’s share price, and thus needs to be responded to.

First, neither Patrick nor anyone on the analyst team has ever had any direct or indirect financial arrangement with Applied DNA Sciences, or any company in our portfolio. John Mauldin does sit on the board of three companies we’ve recommended; however, we include a disclosure any time those companies are so much as mentioned in our weekly and monthly pieces.

Other than the baseless smear campaign lodged against Patrick, the article covered perceived issues with the company’s technology, management, and fundamentals, among other things.

Applied DNA's technology is an integral part of the US military's growing response to the very real threat of cyberwarfare. Before mandating and subsidizing the use of this technology in critical military supply lines, the Pentagon thoroughly tested and validated the company's DNA biotechnology and the operations by which it is deployed. As such, Applied DNA is a de facto part of America's military/intelligence network.

Like other defense contractors, we assume that the company is closely monitored by the military to avoid compromising the technology and its use. The lack of openness about the company's military contracts can be frustrating to some, but it is a necessary part of doing business as a defense industry supplier. More important for investors, it is also a sign that APDN is operating within the military and intelligence industry's scrutiny and rules.

For anyone that still has doubts about APDN’s tight knit connection to the US military, here’s a document from the Defense Logistics Agency on how it uses APDN’s SigNature DNA marking technology in order to monitor and trace sensitive shipments.

The user went on to attack the company’s technology, calling it “1999 era Chinese technology.”

The Department of Defense requires the use of APDN’s technology in its supply lines in order to ensure that everything from cases of ammunition to PATRIOT missiles end up where they need to be.

The Department of Defense is and has been working directly with APDN to implement DNA authentication as part of its cybersecurity efforts and is routinely at the APDN facilities. If anything had been amiss at the company—let alone if it were a shell company as the Seeking Alpha user asserts—I think someone in the government would have noticed.

Although some of APDN’s investors have been involved with failed companies in the past, particularly Crede Capital Group, this isn’t uncommon in the biotech space. Most companies do not turn into multi-billion dollar firms; many fail and/or sell their intellectual property to other companies. This is the nature of the biotech business… and really, business in general. Many of the world’s richest men have made and lost fortunes dozens of times; it’s what entrepreneurs do!

And although APDN’s financing agreement may seem odd when looked at in the context of a large, established company, APDN is still very small and growing. For instance, the point made by the Seeking Alpha user that CEO James Hayward agreed to a dilutive financing arrangement with Arjent Limited that was somehow underhanded in nature is misleading. Dilutive financing agreements are an integral part of the capital raising process and are anything but unusual— especially for small, publicly traded biotechs like APDN.

As for the attacks on APDN’s fundamentals, all you have to do is look at the company’s audited financial statements to see for yourself. At one point, the user went so far as to claim APDN has “no assets.” That statement is false as APDN has over $14.1 million in assets, compared to $1.6 million in liabilities on its balance sheet. If you want to take a look for yourself, click here

The part that really makes us wonder how anyone took this fraud seriously is in the very first sentence, where the user makes no secret that he and his company are short APDN. Right off the bat, you should know he’s biased and trying to drive the price down for his own personal gain.

The article on Seeking Alpha is littered with half-truths and innuendos meant to scare investors into selling for the author’s personal gain—at the expense of a company doing great work. Many of our long-time subscribers have seen this before and understand that this is part of the business. For new ones who haven’t yet experienced a bear raid like this, I feel your pain.

However, one thing that these events do is make stock prices much cheaper than their intrinsic value. Remember: nothing related to the company’s operations changed last week; the fundamentals are still intact..."
Please sign up or sign in to like or comment on this post.